In a head-to-head trial (SURMOUNT-5, 72 weeks), tirzepatide produced more average weight loss than semaglutide — about 20.2% versus 13.7%. But "better" depends on your goal: semaglutide has proven cardiovascular-event reduction and MASH approval, tirzepatide has the sleep-apnea approval, and semaglutide offers an oral option. There is no universal winner.
The short version
Two once-weekly injectable medicines dominate obesity treatment today: semaglutide (Wegovy for weight, Ozempic for diabetes — a GLP-1 agonist) and tirzepatide (Zepbound for weight and sleep apnea, Mounjaro for diabetes — a GLP-1/GIP dual agonist). On average weight loss, tirzepatide wins the head-to-head. On everything else, it depends on what you're treating. This page lays out the trade-offs without crowning a champion. → Semaglutide · Tirzepatide · GLP-1 hub
The head-to-head data (SURMOUNT-5)
The comparison people actually search for was tested directly. In SURMOUNT-5 (adults with obesity, no diabetes, 72 weeks), the average total body-weight loss was:
- Tirzepatide: ~20.2%
- Semaglutide: ~13.7%
Tirzepatide produced greater average weight loss in a direct comparison — the strongest evidence on the narrow "which takes off more weight" question. This aligns with each drug's own pivotal trials: STEP 1 put semaglutide 2.4 mg at ~15% mean at 68 weeks, while SURMOUNT-1 put tirzepatide at ~15% / ~19.5% / ~20.9% at 5 / 10 / 15 mg over 72 weeks.
Why weight loss isn't the only axis
If the decision were only "which produces the bigger number," it would be short. It isn't — because these drugs now carry different proven benefits beyond weight, and those often matter more for a given person than a few percentage points.
Cardiovascular outcomes — advantage semaglutide
In SELECT, semaglutide 2.4 mg reduced major adverse cardiovascular events by about 20% (heart attack, stroke, CV death) over ~3 years in people with established cardiovascular disease and overweight/obesity without diabetes. That is a hard-outcome benefit, not just weight. Tirzepatide's cardiovascular outcome trials (SURPASS-CVOT / SURMOUNT-MMO) are maturing — there is no SELECT-equivalent outcomes claim yet. If proven cardiovascular protection is the priority, semaglutide currently has the evidence. → Obesity & Cardiovascular Health Grade A 🟢
Liver / MASH — advantage semaglutide (for now)
Semaglutide 2.4 mg is FDA-approved for noncirrhotic MASH with F2–F3 fibrosis (accelerated approval), based on the ESSENCE program. Tirzepatide improved MASH resolution in trials (SYNERGY-NASH) but is not FDA-approved for MASH. If a fibrotic fatty liver is a main driver, semaglutide is the approved option today. → GLP-1 & Fatty Liver Grade A 🟢 (semaglutide MASH approval) / B 🟡 (tirzepatide liver data)
Sleep apnea — advantage tirzepatide
Tirzepatide is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity (SURMOUNT-OSA reduced the apnea-hypopnea index). Semaglutide does not hold this indication. If OSA is central, tirzepatide has the label. Grade A 🟢
An oral option — advantage semaglutide
Semaglutide offers a needle-free route: the newly approved oral 25 mg tablet for weight management (the first oral GLP-1 for obesity), plus oral Rybelsus for diabetes. Tirzepatide is injectable only. If avoiding injections matters, semaglutide is the option. Grade B 🟡
Side by side
| Dimension | Semaglutide (Wegovy/Ozempic) | Tirzepatide (Zepbound/Mounjaro) |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Avg weight loss (obesity) | ~15% (STEP 1, 68 wk) | ~15–21% by dose (SURMOUNT-1, 72 wk) |
| Head-to-head (SURMOUNT-5) | ~13.7% | ~20.2% — greater on average |
| Cardiovascular outcomes | Proven MACE reduction (SELECT, ~20%) | CV outcome trials maturing; no SELECT-equivalent claim yet |
| Liver (MASH) | FDA-approved for F2–F3 MASH | Positive trial data; not yet approved |
| Sleep apnea | — | FDA-approved for OSA with obesity |
| Oral option | Yes (oral 25 mg for weight; Rybelsus for diabetes) | No (injectable only) |
| Contraceptive interaction | Not a labeled OCP-specific interaction | Labeled OCP interaction — backup/non-oral method ~4 weeks at start/dose increase |
| Tolerability | GI effects; broadly similar class profile | GI effects; broadly similar class profile |
| Contraindications | MTC/MEN2 boxed warning; pancreatitis caution; avoid pregnancy | Same class contraindications |
| Access/cost | Varies by coverage and supply | Varies by coverage and supply |
Tolerability and side effects — broadly similar
Both drugs share the class side-effect profile: predominantly gastrointestinal (nausea, diarrhea, constipation, vomiting), worst during dose escalation, improving over time; less commonly gallbladder disease, rare pancreatitis, dehydration from severe GI symptoms. Both carry the MTC/MEN2 boxed warning, both advise avoiding pregnancy, and both require a perioperative hold for delayed gastric emptying. One labeled difference: tirzepatide can reduce oral-contraceptive effectiveness around initiation and dose increases (a backup or non-oral method is advised for the first weeks). There is no reliable way to predict who will tolerate one better than the other. → GLP-1 Side Effects Grade B 🟡
Body composition — the same caveat applies to both
Both drugs, like all substantial weight loss, reduce fat-free mass alongside fat — most of the loss is fat, and a DXA "lean mass" number is not "skeletal muscle" or "strength." Neither drug is uniquely muscle-sparing or muscle-wasting; resistance training and adequate protein protect muscle and function on either. Don't choose between them on a muscle claim. → GLP-1 & Muscle Loss Grade C 🟠
Stopping either drug — the same lesson
Withdrawal trials for both (STEP 4 for semaglutide, SURMOUNT-4 for tirzepatide) tell one story: continuing the drug maintains the loss; switching to placebo brings substantial regain as the defended set point reasserts. Semaglutide's STEP 1 extension showed people regained roughly two-thirds of lost weight within about a year of stopping. Neither is a temporary "kickstart"; both are chronic-disease treatment, and maintenance should be planned before starting. → Weight Regain & Maintenance Grade A 🟢
How to actually choose (the honest version)
There is no universal winner. Match the drug to the driver:
- Maximum average weight loss → head-to-head data favor tirzepatide.
- Proven cardiovascular event reduction (e.g., established heart disease) → semaglutide (SELECT).
- MASH with fibrosis → semaglutide (the approved option today).
- Moderate-to-severe sleep apnea with obesity → tirzepatide (the OSA indication).
- Needle-free preference → semaglutide (oral 25 mg).
- Contraception on oral pills → note tirzepatide's OCP interaction.
- Tolerability, comorbidities, pregnancy plans, insurance coverage and supply frequently decide it more than any percentage.
"Better" is patient-specific — this is a conversation with a clinician, not a leaderboard. → Should I Take a GLP-1?
SIGNATURE — "What the evidence says: semaglutide vs tirzepatide"
- What we know: Tirzepatide produced greater average weight loss head-to-head (~20.2% vs ~13.7%). Semaglutide has proven CV-event reduction and MASH approval; tirzepatide has the OSA approval; semaglutide has an oral option.
- What we think: For many patients, the comorbidity that each drug uniquely addresses matters more than the weight-loss gap.
- What we don't know: Tirzepatide's cardiovascular-outcome and MASH-approval status (trials maturing); very-long-term outcomes; who tolerates which drug better.
- What patients should do: Choose on your goals and comorbidities, not the headline percentage; protect muscle; plan maintenance from the start.
Questions patients ask
Is tirzepatide better than semaglutide?
For average weight loss, head-to-head it produced more (~20% vs ~14%). But "better" depends on your goal — CV outcomes and MASH favor semaglutide, OSA and needle-free differ. No universal winner. Grade A 🟢 (weight) / B 🟡 (individual choice)
By how much did tirzepatide beat semaglutide?
In SURMOUNT-5 over 72 weeks, about 20.2% vs 13.7% mean total weight loss — an average, not a guarantee for any individual. Grade A 🟢
Which is better for my heart?
Semaglutide has proven major-cardiovascular-event reduction (SELECT). Tirzepatide's CV outcome trials are still maturing. Grade A 🟢 → Obesity & Cardiovascular Health
Which helps fatty liver?
Semaglutide is FDA-approved for MASH with F2–F3 fibrosis; tirzepatide has promising data but no MASH approval yet. Grade A 🟢 / B 🟡 → GLP-1 & Fatty Liver
Which is better for sleep apnea?
Tirzepatide — it's FDA-approved for moderate-to-severe OSA in adults with obesity. Grade A 🟢
Can I take a pill instead of an injection?
Only semaglutide offers a weight-management oral option (oral 25 mg); tirzepatide is injectable only. Grade B 🟡
Do they have different side effects?
Broadly the same class GI profile and MTC/MEN2 warning; a notable difference is tirzepatide's oral-contraceptive interaction. Grade B 🟡 → GLP-1 Side Effects
Will I regain weight after either one?
Yes — both show substantial regain after stopping. Plan maintenance from the start. Grade A 🟢 → Weight Regain & Maintenance
MYTHS & FAQ (≥15) — Semaglutide vs Tirzepatide
MYTH: "Tirzepatide is simply the better drug." Short answer: Only for average weight loss. Evidence: it won SURMOUNT-5, but semaglutide has CV and MASH advantages and an oral form. Bottom line: no universal winner. Grade A 🟢
MYTH: "The head-to-head number guarantees I'll lose ~20% on tirzepatide." Short answer: No. Evidence: ~20.2% is a trial average; individual results vary widely and depend on tolerating the dose. Bottom line: averages aren't personal predictions. Grade A 🟢
MYTH: "Semaglutide and tirzepatide have identical mechanisms." Short answer: No. Evidence: semaglutide is GLP-1 only; tirzepatide adds GIP. Bottom line: the added incretin is part of why average loss is higher. Grade A 🟢
MYTH: "Both are equally proven to prevent heart attacks." Short answer: No. Evidence: semaglutide has SELECT; tirzepatide's CV outcome trials are still maturing. Bottom line: semaglutide currently has the outcomes evidence. Grade A 🟢
MYTH: "Both are approved for fatty liver." Short answer: No. Evidence: semaglutide is FDA-approved for F2–F3 MASH; tirzepatide is not. Bottom line: semaglutide is the approved liver option today. Grade A 🟢
MYTH: "Both are approved for sleep apnea." Short answer: No. Evidence: only tirzepatide holds the OSA indication. Bottom line: tirzepatide for moderate-to-severe OSA with obesity. Grade A 🟢
MYTH: "There's an oral version of both." Short answer: No. Evidence: only semaglutide has an oral option (oral 25 mg for weight; Rybelsus for diabetes). Bottom line: tirzepatide is injectable only. Grade B 🟡
MYTH: "Whichever loses more weight is best for everyone." Short answer: No. Evidence: comorbidities (heart, liver, sleep apnea) and access often outweigh a few percent. Bottom line: match the drug to your driver. Grade B 🟡
MYTH: "One is clearly easier to tolerate." Short answer: Not predictably. Evidence: both share the class GI profile; individual tolerance varies. Bottom line: you can't reliably predict which suits you better. Grade B 🟡
MYTH: "Only one carries the thyroid warning." Short answer: No. Evidence: both carry the MTC/MEN2 boxed warning. Bottom line: same contraindication for both. Grade A 🟢
MYTH: "The contraceptive interaction applies to both." Short answer: No. Evidence: the oral-contraceptive interaction is labeled for tirzepatide. Bottom line: if you rely on the pill, that's a tirzepatide-specific consideration. Grade B 🟡
MYTH: "You can combine them for more weight loss." Short answer: No. Evidence: both are GLP-1 receptor agonists; combining adds risk without proven benefit. Bottom line: choose one, don't stack them. Grade A 🟢
MYTH: "One protects muscle better than the other." Short answer: Not shown. Evidence: both reduce fat-free mass like all weight loss; training and protein are the protectors. Bottom line: don't decide on a muscle claim. Grade C 🟠 → GLP-1 & Muscle Loss
MYTH: "Switching from one to the other resets everything." Short answer: Not really. Evidence: they share mechanism and the same regain-after-stopping physiology. Bottom line: switching is a clinical decision about tolerability/goals, not a reset. Grade B 🟡
MYTH: "If I stop the more powerful one I'll keep the weight off." Short answer: No. Evidence: withdrawal trials for both show substantial regain. Bottom line: potency doesn't change the need to plan maintenance. Grade A 🟢 → Weight Regain & Maintenance
MYTH: "Diabetes doesn't change the comparison." Short answer: It does. Evidence: weight loss is smaller for both drugs in type 2 diabetes than in obesity without diabetes. Bottom line: expect smaller numbers, and factor diabetes into the choice. Grade B 🟡
KEEP READING
- Semaglutide — the GLP-1-only agent, in full.
- Tirzepatide — the GLP-1/GIP dual agonist, in full.
- GLP-1 Side Effects and GLP-1 & Muscle Loss — the shared concerns, graded.
- GLP-1 & Fatty Liver — why semaglutide holds the MASH approval today.
- Weight Regain & Maintenance — the "forever?" question, for both drugs.
- Should I Take a GLP-1? — a decision tool, not a leaderboard.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: SURMOUNT-5 head-to-head; STEP 1/2/4; SURMOUNT-1/4; SELECT (CV outcomes); ESSENCE and SYNERGY-NASH (MASH); SURMOUNT-OSA; FDA prescribing information for Wegovy/Ozempic and Zepbound/Mounjaro. Educational; not individualized medical advice.
